Long acting GLP-1 receptor agonist (injectable)
Albiglutide flexible dose injection once weekly
ALBI_SC_FLEX_30-50_QW
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.55 (-1.03 to 0.04) | 0.16 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.25 (-5.01 to 4.89) | 0.27 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.50 (0.10 to 2.35) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.23 (0.95 to 5.16) | 0.51 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.49 (-2.20 to 1.28) | 0.27 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 64 to 130 (target week 104) | Placebo | MD -0.35 (-12.61 to 11.14) | 0.38 |
| Type 2 diabetes (adults) | All cause mortality | longest follow-up | Placebo | HR 0.95 (0.60 to 1.47) | 0.35 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.78 (0.46 to 1.36) | 0.69 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.91 (0.73 to 1.14) | 0.54 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.33 (0.84 to 2.13) | 0.57 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.55 (0.26 to 1.14) | 0.85 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.51 (0.22 to 1.20) | 0.85 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.72 (0.37 to 1.40) | 0.81 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.64 (0.57 to 5.82) | 0.49 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.18 (0.37 to 3.52) | 0.38 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.88 (0.39 to 1.99) | 0.61 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 1.09 (0.29 to 4.19) | 0.41 |
Trials
- NCT02465515A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus2015 · 9,463 randomized
- NCT00838916A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.2009 · 779 randomized · 156 weeks